ORAMED PHARMACEUTICALS INC. Contracts & Agreements

Securities Purchase Agreement, dated October 7, 2024, by and between Scilex Holding Company and the investors signatory thereto (Filed With SEC on October 8, 2024)

Amendment No. 1 to Scilex-Oramed SPA, dated October 8, 2024, by and between Scilex Holding Company and Oramed Pharmaceuticals Inc (Filed With SEC on October 8, 2024)

Tranche B Senior Secured Convertible Note, dated October 8, 2024, issued by Scilex Holding Company to the Company (Filed With SEC on October 8, 2024)

Warrant to Purchase Common Stock, dated October 8, 2024, issued by Scilex Holding Company to the Company (Filed With SEC on October 8, 2024)

Purchase and Sale Agreement, dated October 8, 2024, by and among Scilex Holding Company, Silex Pharmaceuticals Inc. and the purchasers signatory thereto (Filed With SEC on October 8, 2024)

Security Agreement, dated October 8, 2024, by and among Scilex Pharmaceuticals Inc., and the purchasers signatory thereto (Filed With SEC on October 8, 2024)

Subordination Agreement, dated October 8, 2024, by and among Scilex Pharmaceuticals Inc., Acquiom Agency Services LLC and other signatories thereto (Filed With SEC on October 8, 2024)

Consent and Amendment, dated as of October 8, 2024, by and between Scilex Holding Company and Oramed Pharmaceuticals Inc (Filed With SEC on October 8, 2024)

Subsidiary Guarantee Amendment, dated October 8, 2024, made by certain of Scilex Holding Company subsidiaries in favor of the holders of that certain Tranche A Note (Filed With SEC on October 8, 2024)

Amended and Restated Security Agreement, dated October 8, 2024, by and among Scilex Holding Company, the Subsidiaries of Scilex Holding Company party thereto, Oramed... (Filed With SEC on October 8, 2024)

Rest of World License Term Sheet, dated October 8, 2024, between Oramed Pharmaceuticals Inc., Scilex Holding Company and the other parties signatories thereto (Filed With SEC on October 8, 2024)

Agreement Among Holders, dated October 8, 2024, by and between Oramed Pharmaceuticals Inc., Acquiom Agency Services LLC and the other signatories thereto (Filed With SEC on October 8, 2024)

Master Services Agreement dated September 23, 2024, between Oramed Ltd. and InClin, Inc (Filed With SEC on September 26, 2024)

Letter Agreement, dated as of September 20, 2024, by and between Oramed Pharmaceuticals Inc. and Scilex Holding Company (Filed With SEC on September 23, 2024)

Representative Form of Indemnification Agreements between Oramed Pharmaceuticals Inc. and each of our directors and officers (Filed With SEC on August 14, 2024)

Employment Agreement, dated June 6, 2024, between Oramed Ltd. and Avraham Gabay (Filed With SEC on August 14, 2024)

Representative Form of Indemnification Agreements between Oramed Pharmaceuticals Inc. and each of our directors and officers (Filed With SEC on May 9, 2024)

At The Market Offering Agreement, dated March 18, 2024, by and among the Company, Rodman & Renshaw LLC and StockBlock Securities LLC (Filed With SEC on March 18, 2024)

Amendment, dated April 27, 2023, to Consulting Agreement by and between Oramed Pharmaceuticals Inc. and Shnida Ltd., entered into as of November 1, 2022, for the services of Nadav... (Filed With SEC on March 6, 2024)

Amendment, dated January 8, 2024, to Consulting Agreement by and between Oramed Pharmaceuticals Inc. and Shnida Ltd., entered into as of November 1, 2022, for the services of... (Filed With SEC on March 6, 2024)

Amendment, dated April 27, 2023, to Employment Agreement by and between Oramed Ltd. and Nadav Kidron, entered into as of November 1, 2022 (Filed With SEC on March 6, 2024)

Amendment, dated January 8, 2024, to Employment Agreement by and between Oramed Ltd. and Nadav Kidron, entered into as of November 1, 2022 (Filed With SEC on March 6, 2024)

Amendment, dated April 27, 2023, to Consulting Agreements by and between Oramed Ltd. and KNRY, Ltd., entered into as of July 1, 2008, for the services of Miriam Kidron (Filed With SEC on March 6, 2024)

Amendment, dated January 8, 2024, to Consulting Agreements by and between Oramed Ltd. and KNRY, Ltd., entered into as of July 1, 2008, for the services of Miriam Kidron (Filed With SEC on March 6, 2024)

Third Amendment, dated April 27, 2023, to Employment Agreement, by and between Oramed Ltd. and David Silberman (Filed With SEC on March 6, 2024)

Fourth Amendment, dated January 8, 2024, to Employment Agreement, by and between Oramed Ltd. and David Silberman (Filed With SEC on March 6, 2024)

Representative Form of Indemnification Agreements between Oramed Pharmaceuticals Inc. and each of our directors and officers (Filed With SEC on March 6, 2024)

Joint Venture Agreement, dated January 22, 2024, among Oramed Pharmaceuticals Inc., Oramed Ltd., Hefei Tianhui Biotech Co., Ltd. and Technowl Limited (Filed With SEC on January 23, 2024)

Securities Purchase Agreement, dated September 21, 2023 by and between Scilex Holding Company and Oramed Pharmaceuticals Inc (Filed With SEC on September 26, 2023)

Senior Secured Promissory Note, dated September 21, 2023 issued to Oramed Pharmaceuticals Inc. by Scilex Holding Company (Filed With SEC on September 26, 2023)

Warrant No. ORMP CS-1 to Purchase Common Stock of Scilex Holding Company (Filed With SEC on September 26, 2023)

Warrant No. ORMP CS-2 to Purchase Common Stock of Scilex Holding Company (Filed With SEC on September 26, 2023)

Warrant No. ORMP CS-3 to Purchase Common Stock of Scilex Holding Company (Filed With SEC on September 26, 2023)

Warrant No. ORMP CS-4 to Purchase Common Stock of Scilex Holding Company (Filed With SEC on September 26, 2023)

Warrant No. ORMP CS-5 to Purchase Common Stock of Scilex Holding Company (Filed With SEC on September 26, 2023)

Scilex Holding Company Specimen Warrant Certificate (Filed With SEC on September 26, 2023)

Registration Rights Agreement, dated September 21, 2023, by and between Oramed Pharmaceuticals Inc. and Scilex Holding Company (Filed With SEC on September 26, 2023)

Subsidiary Guarantee, dated September 21, 2023, by and among Oramed Pharmaceuticals, Acquiom Agency Services LLC, Scilex Holding Company, and certain subsidiaries of Scilex... (Filed With SEC on September 26, 2023)

Security Agreement, dated September 21, 2023, by and among Oramed Pharmaceuticals, Acquiom Agency Services LLC, Scilex Holding Company, and certain subsidiaries of Scilex Holding... (Filed With SEC on September 26, 2023)

Mutual Termination and Release Agreement, dated September 21, 2023, by and between Sorrento Therapeutics, Inc. and Oramed Pharmaceuticals, Inc (Filed With SEC on September 26, 2023)

Second Amendment to Stock Purchase Agreement dated as of August 21, 2023, between Oramed Pharmaceuticals Inc. and Sorrento Therapeutics, Inc (Filed With SEC on August 22, 2023)

First Amendment to Stock Purchase Agreement dated August 9, 2023, by and between Oramed Pharmaceuticals Inc. and Sorrento Therapeutics, Inc (Filed With SEC on August 10, 2023)

Representative Form of Indemnification Agreements between Oramed Pharmaceuticals Inc. and each of our directors and officers (Filed With SEC on August 10, 2023)

Stock Purchase Agreement dated as of August 7, 2023, between Oramed Pharmaceuticals Inc. and Sorrento Therapeutics, Inc (Filed With SEC on August 9, 2023)

Senior Secured, Super-Priority Debtor-in-Possession Loan and Security Agreement dated as of August 9, 2023, among Sorrento Therapeutics, Inc., Scintilla Pharmaceuticals, Inc., the... (Filed With SEC on August 9, 2023)

Description of Securities (Filed With SEC on March 6, 2023)

Consulting Agreement by and between Oramed Pharmaceuticals Inc. and Shnida Ltd., entered into as of November 1, 2022, for the services of Nadav Kidron (Filed With SEC on March 6, 2023)

Employment Agreement by and between Oramed Ltd. and Nadav Kidron, entered into as of November 1, 2022 (Filed With SEC on March 6, 2023)

Second Amendment, dated October 25, 2022, to Employment Agreement, by and between Oramed Ltd. and David Silberman (Filed With SEC on March 6, 2023)

Representative Form of Indemnification Agreements between Oramed Pharmaceuticals Inc. and each of our directors and officers (Filed With SEC on March 6, 2023)

Form of Restricted Stock Unit Notice and Restricted Stock Unit Agreement (Filed With SEC on March 6, 2023)

Oravax Medical, Inc. 2021 Long-Term Incentive Plan (Filed With SEC on March 6, 2023)

Oravax Stock Option Agreement (Filed With SEC on March 6, 2023)

Representative Form of Indemnification Agreements between Oramed Pharmaceuticals Inc. and each of our directors and officers (Filed With SEC on May 12, 2022)

Amendment, dated September 19, 2021, to Consulting Agreements by and between Oramed Ltd. and KNRY, Ltd., entered into as of July 1, 2008, for the services of Nadav Kidron (Filed With SEC on November 24, 2021)

Amendment, dated September 19, 2021, to Consulting Agreements by and between Oramed Ltd. and KNRY, Ltd., entered into as of July 1, 2008, for the services of Miriam Kidron (Filed With SEC on November 24, 2021)

Employment Agreement, dated July 25, 2021, by and between the Company and Michael Rabinowitz (Filed With SEC on November 24, 2021)

First Amendment, dated September 19, 2021, to Employment Agreement, by and between Oramed Ltd. and David Silberman (Filed With SEC on November 24, 2021)

Representative Form of Indemnification Agreements between Oramed Pharmaceuticals Inc. and each of our directors and officers (Filed With SEC on November 24, 2021)

First Amendment, dated September 19, 2021, to Employment Agreement, by and between Oramed Ltd. and Joshua Hexter (Filed With SEC on November 24, 2021)

Engagement Letter, dated as of November 2, 2021, between the Company and H.C. Wainwright & Co., LLC (Filed With SEC on November 4, 2021)

Form of Securities Purchase Agreement, dated as of November 3, 2021 between the Company and each Purchaser in the Offering (Filed With SEC on November 4, 2021)

Equity Distribution Agreement, dated September 1, 2021, by and between the Company and Cantor Fitzgerald & Co (Filed With SEC on September 1, 2021)

Equity Distribution Agreement, dated July 15, 2021, by and between the Company and Canaccord Genuity (Filed With SEC on July 15, 2021)

Employment Agreement, dated May 23, 2021, between Oramed Ltd. and David Silberman (Filed With SEC on July 14, 2021)

Representative Form of Indemnification Agreement between Oramed Pharmaceuticals Inc. and each of its directors and officers (Filed With SEC on July 14, 2021)

Equity Distribution Agreement, dated June 16, 2021, by and between the Company and Canaccord Genuity (Filed With SEC on June 16, 2021)

Second Amendment, dated February 8, 2021, to Employment Agreement, entered into as of May 16, 2019, by and between Oramed Ltd. and Avraham Gabay (Filed With SEC on April 13, 2021)

License Agreement, dated as of March 18, 2021, by and between Oramed Pharmaceuticals Inc., Oramed Ltd. and Oravax Medical Inc (Filed With SEC on March 19, 2021)

Stockholders Agreement, dated as of March 18, 2021, by and between Oramed Pharmaceuticals Inc., Akers Biosciences Inc., Premas Biotech PVT Ltd., Cutter Mill Capital LLC, and Run... (Filed With SEC on March 19, 2021)

Equity Distribution Agreement, dated December 1, 2020, by and between the Company and Canaccord Genuity (Filed With SEC on December 1, 2020)

Description of Securities (Filed With SEC on November 24, 2020)

Clinical Research Organization Services Agreement dated September 16, 2020 and effective as of January 15, 2020, between Oramed Ltd. and Integrium, LLC (Filed With SEC on September 18, 2020)

Clinical Research Organization Services Agreement dated September 2, 2020 and effective as of January 15, 2020, between Oramed Ltd. and Integrium, LLC (Filed With SEC on September 9, 2020)

Amendment to the Service Agreement, dated January 10, 2020, between KNRY Ltd. and Oramed Ltd (Filed With SEC on April 6, 2020)

Amendment to the Equity Distribution Agreement, dated February 10, 2020, between Canaccord Genuity LLC and Oramed Pharmaceuticals Inc (Filed With SEC on April 6, 2020)

Underwriting Agreement, dated February 27, 2020, between Oramed Pharmaceuticals Inc. and National Securities Corporation (Filed With SEC on February 28, 2020)

Form of Underwriters Warrant (Filed With SEC on February 28, 2020)

First Amendment, dated December 19, 2019, to Employment Agreement, entered into as of May 16, 2019, by and between Oramed Ltd. and Avraham Gabay (Filed With SEC on January 9, 2020)

Representative Form of Indemnification Agreement between Oramed Pharmaceuticals Inc. and each of our directors and officers (Filed With SEC on January 9, 2020)

Description of Securities (Filed With SEC on November 27, 2019)

Form of Notice of Stock Option Award and Stock Option Award Agreement (Filed With SEC on November 27, 2019)

Representative Form of Indemnification Agreements between Oramed Pharmaceuticals Inc. and each of our directors and officers (Filed With SEC on November 27, 2019)

Employment Agreement, dated August 18, 2019, between Oramed Ltd. and Joshua Hexter (Filed With SEC on November 27, 2019)

Equity Distribution Agreement, dated September 5, 2019, by and between the Company and Canaccord Genuity (Filed With SEC on September 5, 2019)

Amendment #2 to Clinical Research Organization Services Agreement Protocol # ORA-D-015 between Oramed, Inc. and Integrium, LLC (Filed With SEC on July 10, 2019)

Employment Agreement, dated May 16, 2019, between Oramed Ltd. and Avraham Gabay (Filed With SEC on July 10, 2019)

Representative Form of Indemnification Agreements between Oramed Pharmaceuticals Inc. and each of our directors and officers (Filed With SEC on July 10, 2019)

Amendment #1 to Clinical Research Organization Services Agreement Protocol # ORA-D-015 between Oramed, Inc. and Integrium, LLC (Filed With SEC on July 10, 2019)

Consulting Agreement, dated December 12, 2018, between Oramed Ltd. and Joshua Hexter (Filed With SEC on January 14, 2019)

Amendment to Amended and Restated Employment Agreement, dated October 29, 2018, by and between Oramed Ltd. and Hilla Eisenberg (Filed With SEC on November 28, 2018)

Employment Agreement, dated November 6, 2018, by and between Oramed Ltd. and Mark Hasleton (Filed With SEC on November 28, 2018)

Representative Form of Indemnification Agreements between Oramed Pharmaceuticals Inc. and each of our directors and officers (Filed With SEC on November 28, 2018)

Amendment to Employment Agreement, dated April 15, 2018, between Oramed Ltd. and Joshua Hexter (Filed With SEC on July 12, 2018)

Engagement Letter, dated as of July 2, 2018, between the Company and H.C. Wainwright & Co., LLC (Filed With SEC on July 5, 2018)

Form of Common Stock Purchase Warrant (Filed With SEC on July 5, 2018)

Form of Securities Purchase Agreement, dated as of July 2, 2018 between the Company and each Purchaser in the Offering (Filed With SEC on July 5, 2018)

Clinical Research Organization Services Agreement dated February 14, 2018 and effective as of November 1, 2017, between Oramed Ltd. and Integrium, LLC. (Confidential treatment has... (Filed With SEC on April 9, 2018)

Amendment, dated June 30, 2017, to Consulting Agreements by and between Oramed Ltd. and KNRY, Ltd., entered into as of July 1, 2008, for the services of Miriam Kidron (Filed With SEC on November 29, 2017)

Form of Restricted Stock Unit Notice and Restricted Stock Unit Agreement between the Company and the CSO or CEO (Filed With SEC on November 29, 2017)

Representative Form of Indemnification Agreements between Oramed Pharmaceuticals Inc. and each of our directors and officers (Filed With SEC on November 29, 2017)

Amended and Restated Employment Agreement, dated July 20, 2017, between Oramed Ltd. and Hilla Eisenberg (Filed With SEC on July 21, 2017)

INDEMNIFICATION AGREEMENT (Filed With SEC on April 5, 2017)

AMENDMENT NO. 1 TO AT-THE-MARKET ISSUANCE SALES AGREEMENT (Filed With SEC on April 5, 2017)

Consulting Agreement (Filed With SEC on March 21, 2017)

AGREEMENTAND AMENDMENT NO. 5 (Filed With SEC on January 11, 2017)

FourthAmendment to Employment Agreement (Filed With SEC on January 11, 2017)

INDEMNIFICATIONAGREEMENT (Filed With SEC on January 11, 2017)

AGREEMENT AND AMENDMENT NO. 4 (Filed With SEC on November 25, 2016)

AGREEMENTAND AMENDMENT NO. 4 (Filed With SEC on November 25, 2016)

OramedPharmaceuticals, Inc. | 2 Elza Street, Jerusalem, Israel 93706. | www.oramedpharma.com Phone:011 ###-###-#### | Fax: 011 972-2 ###-###-#### | Email: ***@*** (Filed With SEC on November 25, 2016)

SecondAmendment to Employment Agreement (Filed With SEC on November 25, 2016)

**Confidentialportions have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securitiesand Exchange Commission (the... (Filed With SEC on November 25, 2016)

**Confidentialportions have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securitiesand Exchange Commission (the... (Filed With SEC on January 13, 2016)

AGREEMENTAND AMENDMENT NO. 3 (Filed With SEC on November 25, 2015)

Second Amendment to Employment Agreement (Filed With SEC on November 25, 2015)

Third Amendment to Employment Agreement (Filed With SEC on November 25, 2015)

AGREEMENTAND AMENDMENT NO. 2 (Filed With SEC on November 25, 2015)

Amendment to Employment Agreement (Filed With SEC on November 25, 2015)

COMMONSTOCK PURCHASE WARRANT oramedpharmaceuticals Inc. (Filed With SEC on July 1, 2015)

430 Park Avenue|New York, New York 10022 ###-###-####|www.hcwco.com Member: FINRA/SIPC (Filed With SEC on June 5, 2015)

SECURITIES PURCHASE AGREEMENT (Filed With SEC on June 5, 2015)

ORAMED PHARMACEUTICALS INC. Common Stock (par value $0.012 per share) (Filed With SEC on April 3, 2015)

AGREEMENT AND AMENDMENT NO. 1 (Filed With SEC on November 14, 2014)

AMENDMENT TO CONSULTING AGREEMENTS SIGNED IN JULY 1, 2008 (Filed With SEC on November 14, 2014)

AGREEMENT AND AMENDMENT NO. 1 (Filed With SEC on November 14, 2014)

ORAMED PHARMACEUTICALS INC. AMENDED AND RESTATED 2008 STOCK INCENTIVE PLAN Restricted Stock Unit Notice (Filed With SEC on November 14, 2014)

AGREEMENT AND AMENDMENT NO. 1 (Filed With SEC on November 14, 2014)

**CONFIDENTIAL PORTIONS HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAVE BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION; [***]... (Filed With SEC on November 14, 2014)

SECURITIES PURCHASE AGREEMENT (Filed With SEC on November 4, 2014)

AGREEMENT (Filed With SEC on January 14, 2014)

PLACEMENT AGENCY AGREEMENT between (Filed With SEC on December 26, 2013)

SECURITIES PURCHASE AGREEMENT (Filed With SEC on December 26, 2013)

PLACEMENT AGENCY AGREEMENT (Filed With SEC on July 11, 2013)

SECURITIES PURCHASE AGREEMENT (Filed With SEC on July 11, 2013)

EMPLOYMENT AGREEMENT (Filed With SEC on April 16, 2013)

TEN COM - as tenants in commonTEN ENT - as tenants by the entiretiesJT TEN -as joint tenants with right of survivorship and not as tenants in commonUNIF GIFT MIN ACT -... (Filed With SEC on February 1, 2013)

AMENDMENT NO. 3 TO COMMON STOCK PURCHASE WARRANT OF ORAMED PHARMACEUTICALS INC. (Filed With SEC on February 1, 2013)

AMENDMENT NO. 1 TO COMMON STOCK PURCHASE WARRANT OF ORAMED PHARMACEUTICALS INC. (Filed With SEC on February 1, 2013)

AMENDMENT NO. 1 TO OPTION OF ORAMED PHARMACEUTICALS INC. (Filed With SEC on February 1, 2013)

Sincerely,/s/ Nadav KidronNadav Kidron, CEO (Filed With SEC on February 1, 2013)

COMMON STOCK PURCHASE WARRANT To Purchase ____________ Shares of Common Stock of ORAMED PHARMACEUTICALS INC. (Filed With SEC on December 12, 2012)

CLINICAL TRIAL AGREEMENT (Filed With SEC on December 12, 2012)

SECURITIES PURCHASE AGREEMENT (Filed With SEC on December 12, 2012)

RECITALS: (Filed With SEC on December 12, 2012)

**CONFIDENTIAL PORTIONS HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAVE BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION (THE... (Filed With SEC on December 12, 2012)

SECURITIES PURCHASE AGREEMENT (Filed With SEC on December 12, 2012)

SHARE PURCHASE AGREEMENT (Filed With SEC on March 25, 2011)

Patent Transfer Agreement (Filed With SEC on March 25, 2011)

SECURITIES PURCHASE AGREEMENT (Filed With SEC on March 25, 2011)

COMMON STOCK PURCHASE WARRANT To Purchase [_________] Shares of Common Stock of ORAMED PHARMACEUTICALS INC. (Filed With SEC on March 25, 2011)

PLAN OF CONVERSION OF ORAMED PHARMACEUTICALS INC., a Nevada corporation TO ORAMED PHARMACEUTICALS INC., a Delaware corporation (Filed With SEC on March 14, 2011)

SECURITIESPURCHASE AGREEMENT (Filed With SEC on January 13, 2011)

COMMONSTOCK PURCHASE WARRANT ToPurchase 2,187,500 Shares of Common Stock of ORAMEDPHARMACEUTICALS INC. (Filed With SEC on January 13, 2011)

JOINTVENTURE AGREEMENT (Filed With SEC on July 14, 2010)

ACTIVE PHARMACEUTICALINGREDIENT MANUFACTURING AND CLINICALSUPPLY AGREEMENT (RECOMBINANTHUMAN INSULIN) (Filed With SEC on July 14, 2010)

CLINICALTRIAL AGREEMENT (Filed With SEC on July 9, 2009)

CONSULTING SERVICESAGREEMENT (Filed With SEC on April 22, 2009)

EMPLOYMENTAGREEMENT (Filed With SEC on April 22, 2009)

ORAMEDPHARMACEUTICALS, INC. INDEMNIFICATIONAGREEMENT (Filed With SEC on April 22, 2009)

AGREEMENT (Filed With SEC on January 13, 2009)

AGREEMENT (Filed With SEC on January 7, 2009)

ORAMED PHARMACEUTICALS, INC. INDEMNIFICATION AGREEMENT (Filed With SEC on November 6, 2008)

SECURITIES PURCHASE AGREEMENT (Filed With SEC on July 15, 2008)

COMMON STOCK PURCHASE WARRANT (Filed With SEC on July 15, 2008)

CONSULTING AGREEMENT (Filed With SEC on July 2, 2008)

ORAMED PHARMACEUTICALS INC. 2008 STOCK INCENTIVE PLAN (Filed With SEC on July 2, 2008)

ORAMED PHARMACEUTICALS INC. 2008 STOCK INCENTIVE PLAN NOTICE OF STOCK OPTION AWARD (Filed With SEC on July 2, 2008)

EMPLOYMENT AGREEMENT (Filed With SEC on May 7, 2008)

Master Service Agreement dated January 29, 2008 with OnQ Consulting (Filed With SEC on February 1, 2008)

Form of Expense Agreement dated January 18, 2008 with Leonard Sank (Filed With SEC on February 1, 2008)

Category

Industry

Companies

Contracts

ORAMED PHARMACEUTICALS INC. Contracts & Agreements